Fig 1. Representative tissue microarray cores showing STAT1 immunohistochemical staining.

Fig 1. Representative immunohistochemistry images demonstrating CD4+ (upper), IL-4+ (middle), and IL-13+ (lower) cells in matched human biopsy specimens comparing lymphedematous and contralateral normal upper extremities.

Fig. 8. Single-cell expansion model for melphalan and GC-related mutational signatures.

Fig 5. XPO5 associates with diverse cellular RNAs.

Fig. 2. Example for a lesion that could be downgraded by second-look ultrasound.

FIGURE 3. Case 5. A, Hematoxylin and eosin-stained section of case diagnosed as mixed endometrioid/serous carcinoma. Pictured here is the serous component showing focal papillary architecture, high nuclear grade, and prominent nucleoli. B, Loss of PTEN by immunohistochemistry. C, Aberrant p53 over-expression by immunohistochemistry.

FIGURE 2. In vitro vessel tracking experiments.

Figure 2. Results of training (A), validation (B), and analytical sensitivity (C) studies.

Fig 1. Clonality of normal endometrial glands.

Fig 1.  Mechanisms of regulatory T (Treg) cell suppression.

Extended Data Fig. 2. Expression and co-expression of SARS-CoV-2 entry-associated proteases in ACE2+ airway epithelial cells.

Fig 7. Sox2 directly binds to the miR-486-5p promoter to activate expression in GBM neurospheres.

Figure 1. Innate immune regulation of antiviral defense and tissue toxicity. Virally derived DAMPs and PAMPs activate tissue-resident macrophages.

Figure 1. Relocation of Collapsed Forks to the NPC Depends on Slx5 SUMO-Interacting Motif (SIM) Domains and Mms21-Mediated Sumoylation.

Figure 5. Postoperative T1-weighted MRI in axial (left) and coronal (right) views showing no remnant or residual cyst.

Figure 2. Representative late gadolinium enhancement pattern.

Fig 1. (A) Overall survival (OS) from the start of the first cycle of treatment by Kaplan-Meier estimation with 95% CIs (n = 29). (B) Landmark analysis of OS after completion of 2 cycles of treatment, according to hematologic response category: complete response, very good partial response, or partial response (CR/VGPR/PR) versus stable disease/progression of disease (SD/PD).

Fig. 2. (A) Transcervical access with catheter near the leak; green arrow = transected end of cranial portion of the thoracic duct; red arrow = microcatheter tip within the leak; blue bracket = extravasated contrast. (B) Following transcervical TDE; green bracket = glue within the cranial portion of the thoracic duct.

Fig. 3 Serum REG3α levels and correlates with nonrelapse mortality in patients with GI GVHD.

Fig 1. iCRISPR leads to efficient genome editing within the adult pancreas.

Fig 1. tDCS montage with modeled current density for left dlPFC stimulation.